1. Home
  2. JCE vs ABEO Comparison

JCE vs ABEO Comparison

Compare JCE & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JCE
  • ABEO
  • Stock Information
  • Founded
  • JCE 2007
  • ABEO 1974
  • Country
  • JCE United States
  • ABEO United States
  • Employees
  • JCE N/A
  • ABEO N/A
  • Industry
  • JCE Trusts Except Educational Religious and Charitable
  • ABEO Biotechnology: Pharmaceutical Preparations
  • Sector
  • JCE Finance
  • ABEO Health Care
  • Exchange
  • JCE Nasdaq
  • ABEO Nasdaq
  • Market Cap
  • JCE 262.6M
  • ABEO 289.2M
  • IPO Year
  • JCE N/A
  • ABEO 1980
  • Fundamental
  • Price
  • JCE $15.64
  • ABEO $5.64
  • Analyst Decision
  • JCE
  • ABEO Strong Buy
  • Analyst Count
  • JCE 0
  • ABEO 6
  • Target Price
  • JCE N/A
  • ABEO $18.17
  • AVG Volume (30 Days)
  • JCE 49.7K
  • ABEO 783.9K
  • Earning Date
  • JCE 01-01-0001
  • ABEO 11-13-2025
  • Dividend Yield
  • JCE 9.26%
  • ABEO N/A
  • EPS Growth
  • JCE N/A
  • ABEO N/A
  • EPS
  • JCE N/A
  • ABEO 0.99
  • Revenue
  • JCE N/A
  • ABEO $400,000.00
  • Revenue This Year
  • JCE N/A
  • ABEO N/A
  • Revenue Next Year
  • JCE N/A
  • ABEO $324.71
  • P/E Ratio
  • JCE N/A
  • ABEO $5.70
  • Revenue Growth
  • JCE N/A
  • ABEO N/A
  • 52 Week Low
  • JCE $11.64
  • ABEO $3.93
  • 52 Week High
  • JCE $14.28
  • ABEO $7.54
  • Technical
  • Relative Strength Index (RSI)
  • JCE 49.72
  • ABEO 30.38
  • Support Level
  • JCE $15.47
  • ABEO $5.52
  • Resistance Level
  • JCE $15.81
  • ABEO $5.82
  • Average True Range (ATR)
  • JCE 0.18
  • ABEO 0.29
  • MACD
  • JCE -0.03
  • ABEO -0.16
  • Stochastic Oscillator
  • JCE 31.13
  • ABEO 7.84

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

About ABEO Abeona Therapeutics Inc.

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.

Share on Social Networks: